Aphton Corp. entered a definitive agreement to acquire the privately held Vienna, Austria-based company Igeneon AG for more than $81 million in equity. (BioWorld Today)

With slower-than-expected sales growth of Bexxar, Corixa Corp. decided to turn worldwide rights for the non-Hodgkin's lymphoma product over to partner GlaxoSmithKline plc. (BioWorld Today)

Positive Phase III results for its heart failure drug BiDil certainly played a role in NitroMed Inc.'s ability to raise almost $80 million in a public offering on Wednesday. (BioWorld Today)

In a deal just shy of $150 million, Micromet AG partnered with Serono SA its Phase II monoclonal antibody, MT201, designed to treat prostate and metastatic breast cancer. (BioWorld Today)

Biomira Inc. watched its stock more than double Friday following positive Phase IIb data of its BLP25 liposome vaccine that showed a huge survival benefit for Stage IIIB non-small-cell lung cancer patients. (BioWorld Today)